Advertisement

Clinical Drug Investigation

, Volume 29, Issue 10, pp 647–654 | Cite as

Formulation Selection and Pharmacokinetic Comparison of Fentanyl Buccal Soluble Film with Oral Transmucosal Fentanyl Citrate

A Randomized, Open-Label, Single-Dose, Crossover Study
  • Niraj Vasisht
  • Larry N. Gever
  • Ignacio Tagarro
  • Andrew L. FinnEmail author
Original Research Article

Abstract

Background and Objectives: BioErodible MucoAdhesive (BEMA®) is a new transmucosal drug delivery system designed to improve and ease the administration of drugs by this route. The first product that uses this novel delivery system contains fentanyl and is intended for the treatment of breakthrough pain in opioid-tolerant patients with cancer. The generic name is fentanyl buccal soluble film (FBSF). The objectives of this study were to compare the pharmacokinetic profile of FBSF formulations at three different pHs (pH 6, pH 7.25 and pH 8.5) and to understand the differences in the pharmaco-kinetics of fentanyl from FBSF compared with that of oral transmucosal fentanyl citrate (OTFC).

Methods: This was a randomized, open-label, single-dose, four-period, Latin-square crossover study consisting of a 9-day inpatient treatment period. The study was conducted at a phase 1 clinical research unit in Austin, TX, USA. Twelve healthy subjects were enrolled, nine males and three females, between the ages of 21 and 44 years. Each subject received four 800 µg doses of fentanyl: single doses of the three FBSF formulations (pH 6, pH 7.25 and pH 8.5) and OTFC, with concurrent naltrexone. Plasma fentanyl concentrations were measured over a 48-hour period after each study dose. Pharmacokinetic parameters were calculated and compared.

Results: Peak plasma fentanyl concentrations (Cmax) and overall fentanyl systemic exposure (area under the plasma concentration-time curve from time zero extrapolated to infinity [AUC]) for each of the three FBSF formulations were greater than for OTFC. The pH 7.25 FBSF formulation provided the earliest time to reach Cmax (tmax), the highest Cmax value and the greatest AUC value. Compared with OTFC, peak plasma fentanyl concentrations with pH 7.25 FBSF were significantly higher (mean Cmax 1.67 vs 1.03ng/mL; p<0.05). Overall exposure was also greater with pH 7.25 FBSF than with OTFC (mean AUC 14.5 vs 10.3 ng · h/mL).

Conclusions: All three FBSF formulations produced greater peak plasma concentrations and overall exposure to fentanyl than OTFC. In particular, the pH 7.25 FBSF formulation showed the most favourable pharmacokinetic profile of the three FBSF formulations. In comparison with OTFC, the pH 7.25 FBSF formulation produced the fastest and most efficient fentanyl delivery and was selected for further clinical development.

Keywords

Fentanyl Naltrexone Buccal Mucosa Breakthrough Pain Oral Transmucosal Fentanyl Citrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Funding for the design and conduct of this study, and for the collection, management and analysis of the resulting data, was provided by BioDelivery Sciences International. Funding for the preparation of the manuscript was provided by Meda Pharmaceuticals. Drs Vasisht and Finn are employees and shareholders of BioDelivery Sciences International. Drs Gever and Tagarro are employees of Meda Pharmaceuticals.

The authors would like to thank Lew Fredane (Meda Pharmaceuticals), Bill Wheeler (Meda Pharmaceuticals) and Bill Wargin (PK-PM Associates, LLC) for their assistance with and input into this manuscript.

References

  1. 1.
    Data on file, BioDelivery Sciences International, Inc., Raleigh (NC), 2005Google Scholar
  2. 2.
    Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence, and characteristics. Pain 1990 Jun; 41: 273–81PubMedCrossRefGoogle Scholar
  3. 3.
    McCarberg BH. The treatment of breakthrough pain. Pain Med 2007 Jan-Feb; 8(S1): S8–13PubMedCrossRefGoogle Scholar
  4. 4.
    Actiq® package insert. Salt Lake City (UT): Cephalon Inc., 2007Google Scholar
  5. 5.
    Fentora® package insert. Salt Lake City (UT): Cephalon Inc., 2007Google Scholar
  6. 6.
    Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991 Aug; 75(2): 223–9PubMedCrossRefGoogle Scholar
  7. 7.
    Chandler S. Oral transmucosal fentanyl citrate: a new treatment for breakthrough pain. Am J Hosp Palliat Care 1999 Mar-Apr; 16(2): 489–91PubMedCrossRefGoogle Scholar
  8. 8.
    Gordon D, Schroeder M. Oral transmucosal fentanyl citrate-OTFC (ACTIQ) #103. J Palliat Med 2008 May; 11(4): 633–4PubMedCrossRefGoogle Scholar
  9. 9.
    Mystakidou K, Katsouda E, Parpa E, et al. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. J Opioid Manag 2005 Mar-Apr; 1(1): 36–40PubMedGoogle Scholar
  10. 10.
    Darwish M, Kirby M, Robertson Jr P, et al. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin Pharmacokinet 2006; 45(8): 843–50PubMedCrossRefGoogle Scholar
  11. 11.
    Streisand JB, Zhang J, Niu S, et al. Buccal absorption of fentanyl is pH-dependent in dogs. Anesthesiology 1995 Mar; 82(3): 759–64PubMedCrossRefGoogle Scholar
  12. 12.
    Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Deliv 2006; 4: 1–5CrossRefGoogle Scholar
  13. 13.
    Metropolitan height and weight tables. New York (NY): Metropolitan Life Insurance Company, 1999Google Scholar
  14. 14.
    Foodand Drug Administration, Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products: general considerations. 2003 Mar [online]. Available from URL: http://www.fda.gov/down loads/Drugs/GuidanceComplianceRegulatory Information/ Guidances/ucm070124.pdf [Accessed 2009 Aug 1]Google Scholar
  15. 15.
    Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain: part I. Assessment. P&T 2005 May; 30(5): 296–301Google Scholar
  16. 16.
    Payne R. Recognition and diagnosis of breakthrough pain. Pain Med 2007 Jan-Feb; 8Suppl. 1: S3–7PubMedGoogle Scholar
  17. 17.
    Davies AN. Cancer-related breakthrough pain. Br J Hosp Med (Lond) 2006 Aug; 67(8): 414–6Google Scholar
  18. 18.
    Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002 Feb 1; 94(3): 832–9PubMedCrossRefGoogle Scholar
  19. 19.
    Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blind, placebo-controlled trial for the treatment of breakthrough pain in cancer subjects. J Natl Cancer Inst 1998 Apr; 90(8): 611–6PubMedCrossRefGoogle Scholar
  20. 20.
    Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999 Feb; 79(2-3): 303–12PubMedCrossRefGoogle Scholar
  21. 21.
    Hanks GW, Nugent M, Higgs CM, et al. OTFC Multicentre Study Group. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliat Med 2004 Dec; 18(8): 698–704PubMedCrossRefGoogle Scholar
  22. 22.
    Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006 Nov-Dec; 22(9): 805–11PubMedCrossRefGoogle Scholar
  23. 23.
    Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007 Jul-Aug; 5(7): 327–34PubMedGoogle Scholar
  24. 24.
    Darwish M, Kirby M, Robertson Jr P, et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007 Mar; 47(3): 343–50PubMedCrossRefGoogle Scholar
  25. 25.
    Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001 Mar; 91: 123–30PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Niraj Vasisht
    • 1
  • Larry N. Gever
    • 2
  • Ignacio Tagarro
    • 3
  • Andrew L. Finn
    • 1
    Email author
  1. 1.BioDelivery Sciences International, Inc.RaleighUSA
  2. 2.Meda Pharmaceuticals, Inc.SomersetUSA
  3. 3.Meda PharmaceuticalsMadridSpain

Personalised recommendations